马运峰，博士研究生导师/副教授，
中国免疫学会会员，中国免疫学会青年委员会委员
西安医学会第一届精准医学分会青年委员
研究方向：
肿瘤的免疫治疗及免疫逃逸机制。
1.B细胞与炎症性结肠癌的发生发展。通过研究炎性信号对B细胞的长期刺激，揭示调节性B细胞表型发生变化的机制。
2.基于B细胞的肿瘤疫苗：通过靶向肿瘤相关抗原至B细胞，不但诱导抗肿瘤抗体产生，而且增强体内抗原特异性T细胞的杀伤能力，达到抗肿瘤效果。
个人及工作简历
受教育经历
2004/09– 2009/12 武汉大学 免疫学 硕博连读
1999/09– 2004/06 新乡医学院 临床医疗系 学士
研究工作经历
2017/01-至今 西安交通大学 基础医学院 副教授
2014/04– 2016/12 西安交通大学 基础医学院 讲师
2010/02– 2014/02 美国路易斯维尔大学 肿瘤中心 博士后
主持科研项目
1.国家自然科学基金面上项目，81872026 ，CD19+CD5+CD1dhi调节性B细胞在炎症相关结肠癌免疫逃逸中的作用机制研究，2019/01-2022/12,54万，在研，主持
2.国家自然科学基金面上项目，81472822，经CD19分子将抗原HER2和CD137靶向至B细胞以增强抗乳腺癌免疫应答机制的研究，2015/01-2018/12，75万元，结题 主持。
3.中国博士后科学基金，2014M560787，抗原靶向B细胞增强抗乳腺癌免疫应答的机制研究，2014/05-2016/04，8万元，结题，主持。
4.陕西省自然基金面上项目 2020JM-022，STAT3调控IL-10+B细胞在结直肠癌发生中的机制研究， 2020/01-2021/12， 5万，在研， 主持。
5.陕西省自然基金面上项目 2015JM8385，将抗原MUC1靶向至B细胞增强抗卵巢癌免疫应答机制的研究， 2015/01-2016/12， 3万，结题， 主持。
6.陕西省博士后基金，经 CD19 分子将抗原HER2和 CD137靶向至 B 细胞以增强抗乳腺癌免疫应答机制的研究，2014/05-2016/05， 2万，结题，主持。
7.西安交通大学基本科研业务费（国 际 科 技 合 作 项 目），抗原MUC1 靶向B 细胞打破卵巢癌免疫耐受的机制研究，2015/01-2017/01，10万，结题，主持。
8.西安交通大学新教师科研启动经费，经CD19分子将抗原HER2和CD137靶向至B细胞以增强抗乳腺癌免疫应答机制的研究， 2014/05-2017/05，10万，结题，主持。
9.陕西麦科奥特科技有限公司（横向，）MT3003融合蛋白原核表达与纯化，2014/12-2016/01，1.28万，结题，主持。
学术及科研成果、专利、论文
[1] Lv Z, Zhang P, Li D, Qin M, Nie L, Wang X, Ai L, Feng Z, Odhiambo WO,Ma Y,& Ji, Y.: CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. Oncoimmunology 9: 1747688, 2020.（第一通讯作者）
[2]Lv, Z., Liu, M., Shen, J., Xiang, D.,Ma, Y*,& Ji, Y. (2018). Association of serum interleukin‑10, interleukin‑17A and transforming growth factor‑α levels with human benign and malignant breast diseases. Experimental and therapeutic medicine,15(6), 5475-5480.（第一通讯作者）
[3] Liu, M., Zhao, X.,Ma, Y., Zhou, Y., Deng, M., & Ma, Y. (2018). Transcription factor c‐Maf is essential for IL‐10 gene expression in B cells. Scandinavian journal of immunology,88(3), e12701.
[4]Ma YF#, Chen C#, Li D#, Liu M; Lv ZW; Ji Y; Xu J*. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget.2017 8(5):7614-7624.
[5]Ma YF，Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu JR*.IL-6, IL-8, and TNF-alevels correlate with disease stage in breast cancer patients. Adv Clin Exp Med 2017
26(3):421–426
[6]Ma YF#,Ren Y#, Wu CJ#, Zhao XH, Xu H, Wu DZ, Xu J, Zhang XL, Ji Y*. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer. Mol Immunol 2016, 75, 11-20.
[7] Dai ZJ#*, Liu XH#,Ma YF#, et al. Association between Single Nucleotide Polymorphisms in DNA polymerase Kappa Gene and Breast Cancer Risk in Chinese Han Population: A STROBE-Compliant Observational Study. Medicine (Baltimore). 2016. 95(2): e2466.(共同第一作者)
[8] Wang M#, Wang XJ#,Ma YF#, Ma XB, Dai ZM, Lv Y, Lin S, Liu XH, Yang PT, Dai ZJ*:.PSCA rs2294008 C > T polymorphism contributes to gastric and bladder cancer risk. Ther Clin Risk Manag 2015, 11, 237-45.(共同第一作者)
[9] Dai ZJ#*, Wang BF#,Ma YF#,Kang HF, Diao Y, Zhao Y, Lin S, Lv Y, Wang M, Wang XJ: Current evidence on the relationship between rs1256049 polymorphism in estrogen receptor-beta gene and cancer risk. Int J Clin Exp Med 2014, 7, 5031-40.(共同第一作者)
[10] Ding C#,Ma Y#, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H, Powell D, Yan J* Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun 2013, 4, 2813.(共同第一作者)
[11]Ma Y#, Xiang D#, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J*. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol 2013, 190, 5588-99.
[12]Ma Y#,Chen HD#, Wang Y#, Wang Q, Li Y, Zhao Y, Zhang XL*:Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection. Microbes Infect 2011, 13, 1099-110.
[13]Ma Y, Chen H, Wang Q, Luo F, Yan J, Zhang XL*.IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells. Eur J Immunol 2009, 39, 3357-68.
[14] Wang QL#, Pan Q#,Ma Y#, Wang K, Sun P, Liu S, Zhang XL*: An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine 2009, 27, 6712-22.(共同第一作者)
[15] Liu M, Luo F, Ding C, Albeituni S, Hu X,Ma Y,Cai Y, McNally L, Sanders MA, Jain D, Kloecker G, Bousamra M, Zhang HG, Higashi RM, Lane AN, Fan TW, Yan J .Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype. J Immunol 2015; 195:5055-65;
[16] Gunn L, Ding C, Liu M,Ma Y,Qi C, Cai Y, Hu X, Aggarwal D, Zhang HG, Yan J: Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J Immunol 2012, 189, 2985-94.
[17] Cai Y, Xue F, Fleming C, Yang J, Ding C,Ma Y,Liu M, Zhang HG, Zheng J, Xiong N, Yan J*: Differential developmental requirement and peripheral regulation for dermal Vgamma4 and Vgamma6T17 cells in health and inflammation. Nat Commun 2014, 5, 3986.
[18] Zhao W, Dong Y, Wu C,Ma Y, Jin Y, Ji Y*: MiR-21 overexpression improves osteoporosis by targeting RECK. Mol Cell Biochem 2015, 405, 125-33.
[19] Zhao W, Wu C, Dong Y,Ma Y, Jin Y, Ji Y*: MicroRNA-24 Regulates Osteogenic Differentiation via Targeting T-Cell Factor-1. Int J Mol Sci 2015, 16, 11699-712.
[20] Zhao W, Dong Y, Wu C,Ma Y, Jin Y, Ji Y*. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models. Exp Cell Res. 2016. 340(1): 132-8.
[21] Jiao J, Lv Z, Zhang P, Wang Y, Yuan M, Yu X, Otieno Odhiambo W, Zheng M,
Zhang H,Ma Y, Ji Y (2020). AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines. Neoplasia : an international journal for oncology research 22: 142-153.
[22] Ma YF, He LM, Wu Q,Ma YF,Wang XQ (2018). [Detection of chitinase 3-like 1 combined with other biomarkers for diagnosis of pancreatic cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 38: 450-454.
[23] Yu X, Zhang H, Yuan M, Zhang P, Wang Y, Zheng M, Lv Z, Odhiambo WO, Li C, Liu C,Ma Y,Ji Y (2019). Identification and characterization of a murine model of BCR‑ABL1+ acute B‑lymphoblastic leukemia with central nervous system metastasis. Oncology reports 42: 521-532.
代表性论文
[1] Lv Z, Zhang P, Li D, Qin M, Nie L, Wang X, Ai L, Feng Z, Odhiambo WO,Ma Y,& Ji, Y.: CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. Oncoimmunology 9: 1747688, 2020.（第一通讯作者）
[2]Ma YF#,Ren Y#, Wu CJ#, Zhao XH, Xu H, Wu DZ, Xu J, Zhang XL, Ji Y*. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer. Mol Immunol 2016, 75, 11-20.
[3] Ding C#,Ma Y#, Chen X, Liu M, Cai Y, Hu X, Xiang D, Nath S, Zhang HG, Ye H, Powell D, Yan J* Integrin CD11b negatively regulates BCR signalling to maintain autoreactive B cell tolerance. Nat Commun 2013, 4, 2813.(共同第一作者
[4Ma Y#, Xiang D#, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J*. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol 2013, 190, 5588-99.
[5]Ma Y, Chen H, Wang Q, Luo F, Yan J, Zhang XL*.IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells. Eur J Immunol 2009, 39, 3357-68.
联系方式
联系电话：15619398102
Email：mayunfeng@xjtu.edu.cn
